Advertisement
EDIT vs RCKT
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Rocket Pharmaceuticals (RCKT) Stock Comparison
Key Takeaways
- EDIT is a clinical-stage gene-editing company focused on a single lead candidate, EDIT-401, with no approved products and a cash runway into 2028.
- RCKT is a late-stage gene-therapy developer that recently secured FDA approval for Kresladi and is advancing RP-A501 for Danon disease.
- Editas Medicine has shown stronger recent relative momentum, while Rocket Pharmaceuticals benefits from a commercial-stage milestone and broader pipeline breadth.
- Both companies are pre-profitability and carry high binary, clinical-stage risk tied to trial and regulatory outcomes.
- Market positioning differs sharply: EDIT is a platform-pipeline turnaround story, while RCKT is transitioning toward commercialization of rare-disease therapies.
Introduction
Gene editing and gene therapy represent two of the most closely watched frontiers in biotechnology, and both EDIT (Editas Medicine) and RCKT (Rocket Pharmaceuticals) sit squarely within this high-risk, high-reward space. This stock comparison is relevant for investors and traders evaluating relative performance, momentum, and market positioning among development-stage biotechs. Although both companies target genetic diseases, their business models, pipeline maturity, and near-term catalysts differ materially. Understanding these contrasts can help market participants assess where risk and opportunity currently concentrate.
EDIT Overview and Recent Performance
Editas Medicine (EDIT) is a clinical-stage genome-editing company built around CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology. After discontinuing its reni-cel sickle cell program in late 2024 and restructuring its workforce, the company pivoted toward a single lead candidate, EDIT-401, an experimental one-time in vivo (inside the body) gene-editing therapy designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, an inherited condition marked by dangerously high cholesterol.
Recent weeks have brought meaningful catalysts. The company received clearance in Australia to begin the Phase 1/2 "Strive" clinical trial for EDIT-401, its first human study, and reported encouraging preclinical data showing roughly 90% reductions in LDL cholesterol in non-human primates. These developments fueled positive sentiment, with several analysts upgrading the stock. The company reported cash and investments of about $211.6 million as of mid-2026 and expects its runway to extend into the second half of 2028. Shares have climbed substantially year to date, reflecting renewed investor attention to the EDIT-401 data timeline.
RCKT Overview and Recent Performance
Rocket Pharmaceuticals (RCKT) is a late-stage, now commercial-stage gene-therapy company focused on rare and life-threatening diseases. In March 2026, the FDA (U.S. Food and Drug Administration) granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy approved for children with severe leukocyte adhesion deficiency-I, an ultra-rare genetic immune disorder. The company is preparing for a commercial launch, with patient onboarding expected to begin in the fourth quarter of 2026.
Rocket's most advanced investigational asset, RP-A501 for Danon disease, has also gained traction. The company reached alignment with the FDA on key elements of its pivotal Phase 2 trial, including dose, patient population, and co-primary endpoints, and reported encouraging initial safety data from the first patients treated under a modified protocol. Rocket secured a $150 million credit facility and reported cash and investments of roughly $283.7 million as of mid-2026. Despite these advances, the stock's year-to-date relative performance has been more muted than EDIT's, reflecting the earlier clinical hold and subsequent re-rating of the Danon program.
Trending AI Robots
For traders seeking a more systematic approach to volatile biotech names, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and statistics. Because market conditions shift constantly, only the bots best suited to the current environment earn a place in the Trending AI Robots section. Whether a trader follows a short-term momentum approach or a longer-horizon trend strategy, this section helps surface the bots currently demonstrating the strongest alignment with live market dynamics. Explore the Trending AI Robots page to review the latest selections.
Head-to-Head Comparison
The two companies occupy different stages of the biotech lifecycle. EDIT operates as a platform-driven, pre-clinical-to-early-clinical story concentrated on a single asset, meaning its fortunes hinge heavily on the EDIT-401 data readout and trial execution. Its growth driver is the potential for a one-time treatment addressing a large cardiovascular market, but it has no commercial revenue and remains several years from potential approval. RCKT, by contrast, has a diversified pipeline and a first approved product, Kresladi, giving it a nearer-term commercialization catalyst alongside its cardiovascular programs.
On recent momentum, EDIT has outperformed, reflecting a cleaner catalyst narrative and analyst upgrades. RCKT's positioning is more balanced but was weighed down earlier by a clinical hold and safety concerns that have since been partially resolved. Risk factors also differ: EDIT carries concentrated single-asset and dilution risk, while RCKT faces commercial-execution risk for Kresladi and lingering execution questions around RP-A501. Sector exposure overlaps in gene-based medicine, but EDIT skews toward a broader metabolic-disease opportunity, while RCKT targets ultra-rare cardiovascular and immune disorders.
Tickeron AI Verdict
Based on observable trend consistency, recent relative performance, and the clarity of near-term catalysts, Tickeron's AI would likely lean toward EDIT in the current environment. The stock has demonstrated stronger and more consistent upward momentum, supported by a concrete clinical-trial clearance and favorable analyst revisions. Rocket Pharmaceuticals' broader pipeline and commercial milestone offer stability and diversification, but its more muted relative momentum and earlier safety-related overhang temper its near-term trend profile. This assessment is probabilistic rather than definitive: both names remain highly sensitive to binary clinical and regulatory news, and rankings could shift quickly as new data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and RCKT is a StrongBuy.
Momentum Indicator for EDIT turns negative, indicating new downward trend
EDIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.764) is normal, around the industry mean (3.009). P/E Ratio (-3.909) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for RCKT turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for RCKT crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.696) is normal, around the industry mean (3.009). P/E Ratio (-14.625) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EDIT | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 92 | |
PRICE GROWTH RATING 1..100 | 77 | 87 | |
P/E GROWTH RATING 1..100 | 27 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (11) in the Biotechnology industry is somewhat better than the same rating for EDIT (54). This means that RCKT’s stock grew somewhat faster than EDIT’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that RCKT’s stock grew similarly to EDIT’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as EDIT (99). This means that RCKT’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (77) in the Biotechnology industry is in the same range as RCKT (87). This means that EDIT’s stock grew similarly to RCKT’s over the last 12 months.
RCKT's P/E Growth Rating (15) in the Biotechnology industry is in the same range as EDIT (27). This means that RCKT’s stock grew similarly to EDIT’s over the last 12 months.
| EDIT | RCKT | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 84% |
| Advances ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Declines ODDS (%) | 7 days ago 90% | 7 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- RCKT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while RCKT’s TA Score has 5 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 5 bearish.
- RCKT’s TA Score: 5 bullish, 3 bearish.
Price Growth
EDIT (@Biotechnology) experienced а +5.52% price change this week, while RCKT (@Biotechnology) price change was +1.74% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Reported Earning Dates
EDIT is expected to report earnings on Nov 09, 2026.
RCKT is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FLBR | 26.95 | 0.53 | +2.01% |
| Franklin FTSE Brazil ETF (FLBR) | |||
| FDVV | 61.84 | 0.47 | +0.77% |
| Fidelity High Dividend ETF (FDVV) | |||
| NBTR | 47.94 | 0.05 | +0.10% |
| Neuberger Berman Total Return Bond ETF | |||
| SEPI | 28.55 | 0.01 | +0.04% |
| Shelton Equity Premium Income ETF | |||
| MSFY | 21.42 | -0.11 | -0.51% |
| Kurv Yield Premium Strategy Microsoft (MSFT) ETF (MSFY) | |||
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | +6.61% | ||
| BEAM - EDIT | 66% Closely correlated | +3.06% | ||
| CRSP - EDIT | 63% Loosely correlated | -0.32% | ||
| PRME - EDIT | 62% Loosely correlated | +2.35% | ||
| VYGR - EDIT | 60% Loosely correlated | +6.83% | ||
| SLDB - EDIT | 60% Loosely correlated | +8.11% | ||
More | ||||